Anthos Therapeutics Inc., a new company formed with a $250 million investment from Clarus Ventures successor Blackstone Life Sciences, has in-licensed an antithrombotic agent shelved by Novartis AG. The asset, MAA-868, has the potential to prevent a variety of cardiovascular disorders (CVD) with minimal or no bleeding risk within a new long-acting treatment paradigm, the company said. John Glasspool, a former leader of Novartis' cardiovascular franchise, will lead the company as its CEO and Novartis will hold a minority stake in the company.